Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations | Journal of Medical Genetics

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via CCMG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via CCMG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Cancer genetics

Short report

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Helgadottir H, Ghiorzo P, van Doorn R, et al

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations

Journal of Medical Genetics 2020;57:316-321.